Effects of memantine treatment on language abilities and functional communication: A review of data

REFERENCES

• Ahmed, S., de Jager, C. A., Haigh, A. M., & Garrard, P. (2012). Logopenic aphasia in Alzheimer’s disease: Clinical variant or clinical feature? Journal of Neurology, Neurosurgery & Psychiatry, 83(11), 1056–1062.
   PubMed Web of Science ®Google Scholar
• Bakchine, S., & Loft, H. (2008). Memantine treatment in patients with mild to moderate Alzheimer’s disease: Results of a randomised, double-blind, placebo-controlled 6-month study. Journal of Alzheimer’s Disease, 13(1), 97–107.
   PubMed Web of Science ®Google Scholar
• Bayles, K. A., & Tomoeda, C. K. (1994). Functional linguistic communication inventory. Tucson, AZ: Canyonlands Publishing.
   Google Scholar
• Bayles, K. A., Tomoeda, C. K., Cruz, R. F., & Mahendra, N. (2000). Communication abilities of individuals with late-stage Alzheimer disease. Alzheimer Disease and Associated Disorders, 14(3), 176–181.
   PubMed Web of Science ®Google Scholar
• Berthier, M. L. (2005). Poststroke aphasia: Epidemiology, pathophysiology and treatment. Drugs Aging, 22(2), 163–182.
   PubMed Web of Science ®Google Scholar
• Berthier, M. L., Green, C., Lara, J. P., Higueras, C., Barbancho, M. A., Davila, G., & Pulvermuller, F. (2009). Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Annals of Neurology, 65(5), 577–585.
   PubMed Web of Science ®Google Scholar
• Boxer, A. L., Knopman, D. S., Kaufer, D. I., Grossman, M., Onyike, C., Graf-Radford, N., … Miller, B. L. (2013). Memantine in patients with frontotemporal lobar degeneration: A multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, 12(2), 149–156.
   Google Scholar
• Boxer, A. L., Lipton, A. M., Womack, K., Merrilees, J., Neuhaus, J., Pavlic, D., … Miller, B. L. (2009). An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Disease and Associated Disorders, 23(3), 211–217.
   PubMed Web of Science ®Google Scholar
• Cahana-Amitay, D., Albert, M. L., Pyun, S. B., Westwood, A., Jenkins, T., Wolford, S., & Finley, M. (2011). Language as a stressor in aphasia. aphasiology, 25(2), 593–614.
   PubMed Web of Science ®Google Scholar
• Cardarelli, R., Kertesz, A., & Knebl, J. A. (2010). Frontotemporal dementia: A review for primary care physicians. American Family Physician, 82(11), 1372–1377.
   PubMed Web of Science ®Google Scholar
• Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., & Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. Journal of Child Neurology, 22(5), 574–579.
   PubMed Web of Science ®Google Scholar
• Choudhury, P. R., Lahiri, S., & Rajamma, U. (2012). Glutamate mediated signaling in the pathophysiology of autism spectrum disorders. Pharmacology Biochemistry and Behavior, 100(4), 841–849.
   PubMed Web of Science ®Google Scholar
• Chow, T. W., Fam, D., Graff-Guerrero, A., Verhoeff, N. P., Tang-Wai, D. F., Masellis, M., … Pollock, B. G. (2013). Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: An open-label pilot study. International Journal of Geriatric Psychiatry, 28(3), 319–325.
   Google Scholar
• Chow, T. W., Graff-Guerrero, A., Verhoeff, N. P., Binns, M. A., Tang-Wai, D. F., Freedman, M., … Pollock, B. G. (2011). Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. Neuropsychiatric Disease and Treatment, 7, 415–424.
   PubMed Web of Science ®Google Scholar
• Emre, M., Mecocci, P., & Stender, K. (2008). Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer’s disease. Journal of Alzheimer’s Disease, 14(2), 193–199.
   PubMed Web of Science ®Google Scholar
• Ferris, S., Ihl, R., Robert, P., Winblad, B., Gatz, G., Tennigkeit, F., & Gauthier, S. (2009a). Severe impairment battery language scale: A language-assessment tool for Alzheimer’s disease patients. Alzheimer’s & Dementia, 5(5), 375–379.
   PubMed Web of Science ®Google Scholar
• Ferris, S., Ihl, R., Robert, P., Winblad, B., Gatz, G., Tennigkeit, F., & Gauthier, S. (2009b). Treatment effects of memantine on language in moderate to severe Alzheimer’s disease patients. Alzheimer’s & Dementia, 5(5), 369–374.
   PubMed Web of Science ®Google Scholar
• Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189–198.
   PubMed Web of Science ®Google Scholar
• Forest Pharmaceuticals Inc. (2007). Namenda®: U.S. Prescribing Information. St. Louis, MO: Forest Pharmaceuticals.
   Google Scholar
• Forstl, H., & Kurz, A. (1999). Clinical features of Alzheimer’s disease. European Archives of Psychiatry and Clinical Neurosciences, 249(6), 288–290.
   PubMed Web of Science ®Google Scholar
• Francis, P. T. (2009). Altered glutamate neurotransmission and behaviour in dementia: Evidence from studies of memantine. Current Molecular Pharmacology, 2(1), 77–82.
   PubMedGoogle Scholar
• Frattali, C. M., Thompson, C. K., Holland, A. L., Wohl, C. B., & Ferketic, M. M. (1995). Functional assessment of communication skills for adults (ASHA FACS). Rockville, MD: American Speech-Language-Hearing Association.
   Google Scholar
• Fromm, D., & Holland, A. (1989). Functional communication in Alzheimer’s disease. The Journal of Speech and Hearing Disorders, 54(4), 535–540.
   PubMedGoogle Scholar
• Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997). An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11(Suppl 2), S33–S39.
   PubMed Web of Science ®Google Scholar
• Galasko, D., Schmitt, F., Thomas, R., Jin, S., & Bennett, D. (2005). Detailed assessment of activities of daily living in moderate to severe Alzheimer’s disease. Journal of the International Neuropsychological Society, 11(4), 446–453.
   PubMed Web of Science ®Google Scholar
• Gauthier, S., Loft, H., & Cummings, J. (2008). Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: A pooled data analysis. International Journal of Geriatric Psychiatry, 23(5), 537–545.
   PubMed Web of Science ®Google Scholar
• Ghezzi, A., Goretti, B., Portaccio, E., Roscio, M., & Amato, M. P. (2010). Cognitive impairment in pediatric multiple sclerosis. Neurological Sciences, 31(Suppl 2), S215–S218.
   PubMed Web of Science ®Google Scholar
• Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., … Grossman, M. (2011). Classification of primary progressive aphasia and its variants. Neurology, 76(11), 1006–1014.
   PubMed Web of Science ®Google Scholar
• Grossberg, G. T., Manes, F., Allegri, R. F., Gutierrez-Robledo, L. M., Gloger, S., Xie, L., … Graham, S. (2013). The safety, tolerability, and efficacy of once-daily memantine (28 mg): A multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-tosevere Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs, 27(6), 469–478.
   Google Scholar
• Honig, L. S., & Mayeux, R. (2001). Natural history of Alzheimer’s disease. Aging (Milano), 13(3), 171–182.
   PubMedGoogle Scholar
• Isaacs, B., & Kennie, A. T. (1973). The Set test as an aid to the detection of dementia in old people. The British Journal of Psychiatry, 123(575), 467–470.
   PubMed Web of Science ®Google Scholar
• Johnson, N. A., Rademaker, A., Weintraub, S., Gitelman, D., Wienecke, C., & Mesulam, M. (2010). Pilot trial of memantine in primary progressive aphasia. Alzheimer Disease and Associated Disorders, 24(3), 308.
   PubMed Web of Science ®Google Scholar
• Kertesz, A. (1982). Western aphasia battery (WAB). San Antonio, TX: The Psychological Corporation.
   Google Scholar
• Kinney, J. M., & Stephens, M. A. (1989). Caregiving hassles scale: Assessing the daily hassles of caring for a family member with dementia. Gerontologist, 29(3), 328–332.
   PubMed Web of Science ®Google Scholar
• Kitamura, S., Honma, A., Nakamura, Y., & Yoshimura, I. (2011). Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer’s disease: Efficacy, safety and recommended dose. Japanese Journal of Geriatric Psychiatry, 22, 300–311.
   Google Scholar
• Litvinenko, I. V., Odinak, M. M., Mogil’naya, V. I., & Perstnev, S. V. (2010). Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson’s disease complicated by dementia. Neuroscience and Behavioral Physiology, 40(2), 149–155.
   PubMedGoogle Scholar
• Lovera, J. F., Frohman, E., Brown, T. R., Bandari, D., Nguyen, L., Yadav, V., … Bourdette, D. (2010). Memantine for cognitive impairment in multiple sclerosis: A randomized placebo-controlled trial. Multiple Sclerosis, 16(6), 715–723.
   PubMed Web of Science ®Google Scholar
• McShane, R., Areosa Sastre, A., & Minakaran, N. (2006). Memantine for dementia. Cochrane Database of Systematic Reviews, (2), CD003154.
   Google Scholar
• Mecocci, P., Bladstrom, A., & Stender, K. (2009). Effects of memantine on cognition in patients with moderate to severe Alzheimer’s disease: Post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. International Journal of Geriatric Psychiatry, 24(5), 532–538.
   PubMed Web of Science ®Google Scholar
• Mesulam, M. M. (2003). Primary progressive aphasia--A language-based dementia. The New England Journal of Medicine, 349(16), 1535–1542.
   PubMed Web of Science ®Google Scholar
• Morris, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., … Clark, C. (1989). The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology, 39(9), 1159–1165.
   PubMed Web of Science ®Google Scholar
• Ocklenburg, S., Arning, L., Hahn, C., Gerding, W. M., Epplen, J. T., Gunturkun, O., & Beste, C. (2011). Variation in the NMDA receptor 2B subunit gene GRIN2B is associated with differential language lateralization. Behavioural Brain Research, 225(1), 284–289.
   PubMed Web of Science ®Google Scholar
• Panisset, M., Roudier, M., Saxton, J., & Boller, F. (1994). Severe impairment battery. A neuropsychological test for severely demented patients. Archives of Neurology, 51(1), 41–45.
   PubMed Web of Science ®Google Scholar
• Parsons, C. G., Danysz, W., & Quack, G. (1999). Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist—A review of preclinical data. Neuropharmacology, 38(6), 735–767.
   PubMed Web of Science ®Google Scholar
• Parsons, C. G., Stoffler, A., & Danysz, W. (2007). Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—Too little activation is bad, too much is even worse. Neuropharmacology, 53(6), 699–723.
   PubMed Web of Science ®Google Scholar
• Peskind, E. R., Potkin, S. G., Pomara, N., Ott, B. R., Graham, S. M., Olin, J. T., & McDonald, S. (2006). Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. The American Journal of Geriatric Psychiatry, 14(8), 704–715.
   PubMed Web of Science ®Google Scholar
• Pomara, N., Ott, B. R., Peskind, E., & Resnick, E. M. (2007). Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: Secondary analyses from a placebo-controlled randomized trial. Alzheimer Disease and Associated Disorders, 21(1), 60–64.
   PubMed Web of Science ®Google Scholar
• Porsteinsson, A. P., Grossberg, G. T., Mintzer, J., & Olin, J. T. (2008). Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial. Current Alzheimer Research, 5(1), 83–89.
   PubMed Web of Science ®Google Scholar
• Portugal Mda, G., Marinho, V., & Laks, J. (2011). Pharmacological treatment of frontotemporal lobar degeneration: Systematic review. Revista Brasileira de Psiquiatria, 33(1), 81–90.
   PubMed Web of Science ®Google Scholar
• Pulvermüller, F., & Berthier, M. L. (2008). Aphasia therapy on a neuroscience basis. Aphasiology, 22(6), 563–599.
   PubMed Web of Science ®Google Scholar
• Reilly, J., Rodriguez, A. D., Lamy, M., & Neils-Strunjas, J. (2010). Cognition, language, and clinical pathological features of non-Alzheimer’s dementias: An overview. Journal of Communication Disorders, 43(5), 438–452.
   PubMed Web of Science ®Google Scholar
• Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., & Mobius, H. J. (2003). Memantine in moderate-to-severe Alzheimer’s disease. The New England Journal of Medicine, 348(14), 1333–1341.
   PubMed Web of Science ®Google Scholar
• Ripich, D. N. (1994). Functional communication with AD patients: A caregiver training program. Alzheimer Disease and Associated Disorders, 8(Suppl 3), 95–109.
   PubMed Web of Science ®Google Scholar
• Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer’s disease. The American Journal of Psychiatry, 141(11), 1356–1364.
   PubMed Web of Science ®Google Scholar
• Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., … Girardi, P. (2012). The role of memantine in the treatment of psychiatric disorders other than the dementias: A review of current preclinical and clinical evidence. CNS Drugs, 26(8), 663–690.
   PubMed Web of Science ®Google Scholar
• Saur, D., & Hartwigsen, G. (2012). Neurobiology of language recovery after stroke: Lessons from neuroimaging studies. Archives of Physical Medicine and Rehabilitation, 93(1 Suppl), S15–S25.
   PubMed Web of Science ®Google Scholar
• Savundranayagam, M. Y., Hummert, M. L., & Montgomery, R. J. (2005). Investigating the effects of communication problems on caregiver burden. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 60(1), S48–55.
   PubMed Web of Science ®Google Scholar
• Saxton, J., Hofbauer, R. K., Woodward, M., Gilchrist, N. L., Potocnik, F., Hsu, H. A., … Perhach, J. L. (2012). Memantine and functional communication in Alzheimer’s disease: Results of a 12-week, international, randomized clinical trial. Journal of Alzheimer’s Disease, 28(1), 109–118.
   PubMed Web of Science ®Google Scholar
• Schmitt, F. A., Ashford, W., Ernesto, C., Saxton, J., Schneider, L. S., Clark, C. M., … Thal, L. J. (1997). The severe impairment battery: Concurrent validity and the assessment of longitudinal change in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11(Suppl 2), S51–S56.
   PubMed Web of Science ®Google Scholar
• Schmitt, F. A., van Dyck, C. H., Wichems, C. H., & Olin, J. T. (2006). Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: An exploratory reanalysis. Alzheimer Disease and Associated Disorders, 20(4), 255–262.
   PubMed Web of Science ®Google Scholar
• Schulz, J. B., Rainer, M., Klunemann, H. H., Kurz, A., Wolf, S., Sternberg, K., & Tennigkeit, F. (2011). Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer’s disease: Results of a 16-week open-label trial. Journal of Alzheimer’s Disease, 25(3), 463–475.
   PubMed Web of Science ®Google Scholar
• Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., & Gergel, I. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA, 291(3), 317–324.
   PubMed Web of Science ®Google Scholar
• Tocco, M. T., & Graham, S. M. (2010). Effects of memantine treatment on language abilities and functional communication in patients with moderate to severe Alzheimer’s disease: A review of data [abstract]. Alzheimer’s & Dementia, 6(Suppl. 4), S304.
   Google Scholar
• Tocco, M. T., Saxton, J., Tariot, P., Hofbauer, R. K., Resnick, E. M., & Graham, S. M. (2008). Effects of memantine on language and functional communication in patients with moderate to severe Alzheimer’s disease receiving stable doses of donepezil [abstract]. Neurology, 70(Suppl. 1), A99.
   PubMed Web of Science ®Google Scholar
• van der Kam, P., Mol, F., & Wimmers, M. (1971). Beoordelingsschaal voor oudere patienten (BOP). Deventer: Van Loghum Slaterus.
   Google Scholar
• van Dyck, C. H., Tariot, P. N., Meyers, B., & Resnick, E. M. (2007). A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Disease and Associated Disorders, 21(2), 136–143.
   PubMed Web of Science ®Google Scholar
• Verma, M., & Howard, R. J. (2012). Semantic memory and language dysfunction in early Alzheimer’s disease: A review. International Journal of Geriatric Psychiatry, 27(12), 1209–1217.
   Google Scholar
• Weiner, M. W., Sadowsky, C., Saxton, J., Hofbauer, R. K., Graham, S. M., Yu, S. Y., … Perhach, J. L. (2011). Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer’s disease. Alzheimer’s & Dementia, 7(4), 425–435.
   PubMed Web of Science ®Google Scholar
• Woodward, M. (2013). Aspects of communication in Alzheimer’s disease: Clinical features and treatment options. International Psychogeriatrics, 25(6), 877–885.
   PubMed Web of Science ®Google Scholar
• Wroolie, T. E., Kenna, H. A., Williams, K. E., Powers, B. N., Holcomb, M., Lazzeroni, L., & Rasgon, N. L. (2009). Cognitive effects of memantine in postmenopausal women at risk of dementia: A pilot study. Acta Neurologica Scandinavica, 119(3), 172–179.
   PubMed Web of Science ®Google Scholar
• Zec, R. F., Landreth, E. S., Fritz, S., Grames, E., Hasara, A., Fraizer, W., … Manyam, B. (1999). A comparison of phonemic, semantic, and alternating word fluency in Parkinson’s disease. Archives of Clinical Neuropsychology, 14(3), 255–264.
   PubMed Web of Science ®Google Scholar